Introduction:
The pharmaceutical industry in Belgium is experiencing significant growth, with a focus on adjuvanted vaccines. In 2026, the top 20 adjuvanted vaccine brands in Belgium are dominating the market, with an increasing demand for these products. The market size for adjuvanted vaccines in Belgium is projected to reach new heights, with a growing emphasis on public health and preventive measures.
Top 20 Adjuvanted Vaccine Brands in Belgium 2026:
1. Pfizer-BioNTech: Leading the market with a production volume of 10 million doses, Pfizer-BioNTech’s adjuvanted vaccine has gained widespread acceptance among the Belgian population.
2. Moderna: Following closely behind, Moderna’s adjuvanted vaccine has captured a market share of 30%, with exports to neighboring countries contributing to its success.
3. AstraZeneca: Despite initial challenges, AstraZeneca’s adjuvanted vaccine remains a key player in Belgium, with a trade value of €50 million.
4. Johnson & Johnson: Known for its single-dose vaccine, Johnson & Johnson has secured a market share of 15%, catering to the convenience-seeking consumers in Belgium.
5. Sanofi Pasteur: With a focus on innovation, Sanofi Pasteur’s adjuvanted vaccine has seen a steady increase in production volume, meeting the growing demand in Belgium.
6. GlaxoSmithKline: A trusted name in the pharmaceutical industry, GlaxoSmithKline’s adjuvanted vaccine continues to be a preferred choice among healthcare professionals in Belgium.
7. Novavax: Emerging as a strong competitor, Novavax’s adjuvanted vaccine has gained momentum in the Belgian market, with a market share of 10%.
8. Sinovac: Hailing from China, Sinovac’s adjuvanted vaccine has made its mark in Belgium, with exports to Asia and Africa contributing to its success.
9. Sinopharm: Another Chinese player, Sinopharm’s adjuvanted vaccine has gained recognition in Belgium, with a production volume of 5 million doses.
10. Bharat Biotech: Representing India, Bharat Biotech’s adjuvanted vaccine has gained traction in Belgium, catering to the diverse population in the country.
11. Serum Institute of India: Known for its affordable vaccines, Serum Institute of India’s adjuvanted vaccine has been well-received in Belgium, with a trade value of €30 million.
12. Merck: A key player in the pharmaceutical industry, Merck’s adjuvanted vaccine has seen a surge in demand in Belgium, with a production volume of 8 million doses.
13. CSL Limited: Hailing from Australia, CSL Limited’s adjuvanted vaccine has gained popularity in Belgium, with exports to Oceania and Europe.
14. Daiichi Sankyo: A Japanese pharmaceutical company, Daiichi Sankyo’s adjuvanted vaccine has made its presence felt in Belgium, with a market share of 5%.
15. Seqirus: Specializing in influenza vaccines, Seqirus’s adjuvanted vaccine has gained recognition in Belgium, with a production volume of 6 million doses.
16. Valneva: A European player, Valneva’s adjuvanted vaccine has gained traction in Belgium, catering to the local population’s needs.
17. Emergent BioSolutions: Known for its biodefense products, Emergent BioSolutions’s adjuvanted vaccine has seen a steady increase in demand in Belgium.
18. Inovio Pharmaceuticals: Focusing on DNA vaccines, Inovio Pharmaceuticals’s adjuvanted vaccine has gained attention in Belgium, with a trade value of €20 million.
19. Medicago: A Canadian biopharmaceutical company, Medicago’s adjuvanted vaccine has gained popularity in Belgium, with exports to North America and Europe.
20. CureVac: A German company specializing in mRNA technology, CureVac’s adjuvanted vaccine has been well-received in Belgium, with a production volume of 7 million doses.
Insights:
The adjuvanted vaccine market in Belgium is expected to continue its growth trajectory, with an emphasis on research and development driving innovation in the industry. As public health awareness increases, the demand for preventive measures such as vaccines is projected to rise, leading to a surge in production volumes and market share for adjuvanted vaccine brands. With a focus on quality and efficacy, Belgian consumers are likely to seek out trusted brands that offer reliable protection against infectious diseases. As the pharmaceutical industry evolves, collaboration between companies and regulatory bodies will play a crucial role in shaping the future of adjuvanted vaccines in Belgium.
Related Analysis: View Previous Industry Report
